PGNX News and Press, Progenics Pharmaceuticals Inc. From 05/07/20

Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio Planned NDA Submission for PyL TM On Track for Early Third Quarter 2020 First Quarter Sal...

NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quar...

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (...

Merger activity increased last week with one new deal announced and seven deals closing. At a time when more than 10 deals trade with spreads of over 30% and 23 trade with spreads of over 10%, it is encouraging to see so many deals close including the acquisition of Sprint by T-Mobile (TMUS). ...

Progenics Pharmaceuticals (NASDAQ: PGNX ): Q4 GAAP EPS of -$0.13 beats by $0.12 . More news on: Progenics Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top line results from the Phase 3 CONDOR trial of PyL™ highlights the potential of our...

Merger activity increased last week with five new deals announced and one deal closing. The new deals announced last week were across different sectors. Two of the five new deals belong to the financial services sector, one from the real estate sector and two from the technology sector. Acco...

The boards of Lantheus Holdings ( LNTH -0.5% ) and Progenics Pharmaceuticals ( PGNX +11.4% ) have agreed to amend their merger agreement, first announced in October 2019. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Merger & ac...

Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combine...

Back in October, Lantheus Holdings ( LNTH ) and Progenics Pharmaceuticals ( PGNX ) publicized their agreement for Lantheus to purchase Progenics in an all-stock transaction. Despite some synergies between the companies, it appears a large portion of Progenics’ shareholders are not in ...